InvestSMART

Neuren Pharmaceuticals Limited (ASX: NEU) - Announcements

- Current share price for NEU : $20.210

ASX company news and announcements for Neuren Pharmaceuticals Limited (NEU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Neuren Pharmaceuticals Limited (NEU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Neuren Pharmaceuticals Limited (NEU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Neuren Pharmaceuticals Limited (NEU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$2,562 Ceasing to be a substantial holder 19 Jul 2024 11:27AM $20.365 $20.210 fallen by 0.76%
$2,562 Neuren receives Rare Pediatric Disease Designation from FDA 19 Jul 2024 9:59AM $20.780 $20.210 fallen by 2.74%
$2,562 Final Director's Interest Notice - T Scott 2 Jul 2024 4:49PM n/a $20.210 n/a
$2,562 Application for quotation of securities - NEU 17 Jun 2024 4:28PM $19.800 $20.210 risen by 2.07%
$2,562 Change of Director's Interest Notice - J Basile 13 Jun 2024 1:16PM $19.010 $20.210 risen by 6.31%
$2,562 Corporate Presentation, 29 May 2024 29 May 2024 9:57AM $23.110 $20.210 fallen by 12.55%
$2,562 Results of Meeting 28 May 2024 4:45PM $23.110 $20.210 fallen by 12.55%
$2,562 AGM Chair Address & CEO Presentation 28 May 2024 2:00PM $23.195 $20.210 fallen by 12.87%
$2,562 Investor presentation, 27 May 2024 27 May 2024 10:02AM $20.710 $20.210 fallen by 2.41%
$2,562 Phase 2 trial shows significant improvements in Pitt Hopkins 27 May 2024 9:57AM $20.710 $20.210 fallen by 2.41%
$2,562 Trading Halt 23 May 2024 9:14AM $20.710 $20.210 fallen by 2.41%
$2,562 Neuren CEO to present at BIO & Jefferies conferences in US 16 May 2024 11:25AM $22.095 $20.210 fallen by 8.53%
$2,562 Investor presentation, 15 May 2024 15 May 2024 9:43AM $20.200 $20.210 risen by 0.05%
$2,562 DAYBUE Q1 net sales US$75.9m, full-year guidance US$370-420m 9 May 2024 10:09AM $20.100 $20.210 risen by 0.55%
$2,562 Notification of cessation of securities - NEU 7 May 2024 4:31PM $20.250 $20.210 fallen by 0.20%
$2,562 Notification of cessation of securities - NEU 26 Apr 2024 4:40PM $18.650 $20.210 risen by 8.36%
$2,562 Virtual AGM online guide 26 Apr 2024 9:57AM $18.850 $20.210 risen by 7.21%
$2,562 Notice of Annual General Meeting/Proxy Form 26 Apr 2024 9:55AM $18.850 $20.210 risen by 7.21%
$2,562 Q1 2024 quarterly activity and cash flow report 24 Apr 2024 10:05AM $19.300 $20.210 risen by 4.72%
$2,562 Trofinetide accepted for Priority Review by Health Canada 23 Apr 2024 9:43AM $19.280 $20.210 risen by 4.82%
$2,562 Appendix 4G 23 Apr 2024 9:21AM $19.280 $20.210 risen by 4.82%
$2,562 2023 Annual Report to shareholders 23 Apr 2024 9:16AM $19.280 $20.210 risen by 4.82%
$2,562 Application for quotation of securities - NEU 8 Apr 2024 4:26PM $20.800 $20.210 fallen by 2.84%
$2,562 Application for quotation of securities - NEU 12 Mar 2024 2:24PM $20.740 $20.210 fallen by 2.56%
$2,562 2023 Results webinar 29 Feb 2024 4:17PM $19.360 $20.210 risen by 4.39%

226 - 250 of 833 results

Page 10 of 34

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.